DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/wkfpng/cinquil) has announced the addition of the "Cinquil (Reslizumab) (Asthma) - Forecast and Market Analysis to 2023" report to their offering.
Cinquil is a humanized mAb targeting IL-5, a cytokine that regulates the activation of eosinophils. Teva added Cinquil to its portfolio as part of the Cephalon acquisition in 2011. Cinquil is currently being studied in both eosinophilic esophagitis and asthma. The importance of eosinophilic airway inflammation, which is present in 40- 60% of the severe asthmatic population, is evidenced by the number of companies targeting this patient segment. Of all the products in the pipeline that lead to eosinophil depletion, the most advanced ones target the IL-5 pathway.
- Overview of Asthma, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Cinquil including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Cinquil for the top eight countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Unmet Need and Opportunity
7 Pipeline Assessment
8 Cinquil (reslizumab)
For more information visit http://www.researchandmarkets.com/research/wkfpng/cinquil